Česká republika čelí výraznému stárnutí populace, což představuje nové výzvy pro zdravotní a sociální systémy. Počet osob starších 65 let tvoří zhruba 20,6 % populace, přičemž do roku 2100 by tato skupina mohla dosáhnout téměř třetiny populace. Potřeba zdravotní péče se s věkem exponenciálně zvyšuje, téměř 64 % osob nad 65 let trpí nějakou formou chronického onemocnění. Efektivní management potřeb seniorů je zásadní pro zlepšení jejich kvality života a optimalizaci zdravotnických zdrojů. Data ukazují, že senioři v péči geriatrů mají vyšší průměrné skóre Charlsonové komorbiditního indexu a čelí složitějším zdravotním výzvám než senioři ošetřovaní mimo geriatrickou péči. Mapování potřeb geriatrických pacientů na základě dostupných zdravotnických dat je ale složité, neboť nejsou definováni pouze věkem, ale mají i specifické potřeby přesahující zdravotní systém. Navíc existují výrazné regionální rozdíly v dostupnosti i tak personálně výrazně poddimenzované geriatrické péče. Zavedení nových kódů pro popis zdravotních stavů a intervencí a jejich důsledné vykazování mohou vést k přesnější identifikaci geriatrického pacienta ve zdravotních datech a umožní mapování potřeb geriatrických pacientů a úpravy systému zdravotní péče tak, aby byl připraven na demografické výzvy spojené se stárnutím české populace. Korespondenční adresa: RNDr. Jiří Jarkovský, Ph.D. Ústav zdravotnických informací a statistiky ČR Palackého náměstí 4 P. O. BOX 60, 128 01 Praha 2 e-mail: Jiri.Jarkovsky@uzis.cz

The Czech Republic is facing a significantly ageing population, which poses new challenges for health and social systems. The number of people over 65 years of age accounts for about 20.6 % of the population, and by 2100 this group could reach almost a third of the population. The need for healthcare increases exponentially with age, with almost 64 % of people over 65 suffering from some form of chronic disease. Effective management of the needs of the elderly is essential to improve their quality of life and optimise healthcare resources. Data show that seniors in geriatric care have higher average Charlson Comorbidity Index scores and face more complex health challenges than seniors cared for outside of geriatric care. However, mapping the needs of geriatric patients based on available healthcare data is difficult because they are not defined by age alone, but have specific needs that transcend the healthcare system. In addition, there are significant regional differences in the availability of already significantly understaffed geriatric care. The introduction of new codes to describe health conditions and interventions and their consistent reporting may lead to more accurate identification of geriatric patients in health data and allow mapping of geriatric patients’ needs and adjustments to the healthcare system to be prepared for the demographic challenges associated with the ageing of the Czech population.

• MeSH
• geriatrie organizace a řízení   statistika a číselné údaje   MeSH
• hospitalizace statistika a číselné údaje   MeSH
• komorbidita MeSH
• lidé MeSH
• senioři MeSH
• stárnutí * MeSH
• zdravotní služby pro seniory * organizace a řízení   statistika a číselné údaje   MeSH
• Check Tag
• lidé MeSH
• senioři MeSH
• Geografické názvy
• Česká republika MeSH

BACKGROUND AND AIMS: The question of when and how to treat truly asymptomatic patients with severe aortic stenosis (AS) and normal left ventricular (LV) systolic function is still subject to debate and ongoing research. Here, the results of extended follow-up of the AVATAR trial are reported (NCT02436655, ClinicalTrials.gov). METHODS: The AVATAR trial randomly assigned patients with severe, asymptomatic AS and LV ejection fraction ≥ 50% to undergo either early surgical aortic valve replacement (AVR) or conservative treatment with watchful waiting strategy. All patients had negative exercise stress testing. The primary hypothesis was that early AVR will reduce a primary composite endpoint comprising all-cause death, acute myocardial infarction, stroke, or unplanned hospitalization for heart failure (HF), as compared with conservative treatment strategy. RESULTS: A total of 157 low-risk patients (mean age 67 years, 57% men, mean Society of Thoracic Surgeons score 1.7%) were randomly allocated to either the early AVR group (n = 78) or the conservative treatment group (n = 79). In an intention-to-treat analysis, after a median follow-up of 63 months, the primary composite endpoint outcome event occurred in 18/78 patients (23.1%) in the early surgery group and in 37/79 patients (46.8%) in the conservative treatment group [hazard ratio (HR) early surgery vs. conservative treatment 0.42; 95% confidence interval (CI) 0.24-0.73, P = .002]. The Kaplan-Meier estimates for individual endpoints of all-cause death and HF hospitalization were significantly lower in the early surgery compared with the conservative group (HR 0.44; 95% CI 0.23-0.85, P = .012, for all-cause death and HR 0.21; 95% CI 0.06-0.73, P = .007, for HF hospitalizations). CONCLUSIONS: The extended follow-up of the AVATAR trial demonstrates better clinical outcomes with early surgical AVR in truly asymptomatic patients with severe AS and normal LV ejection fraction compared with patients treated with conservative management on watchful waiting.

• MeSH
• aortální chlopeň chirurgie   MeSH
• aortální stenóza * chirurgie   mortalita   terapie   MeSH
• asymptomatické nemoci terapie   MeSH
• avatar MeSH
• cévní mozková příhoda MeSH
• chirurgická náhrada chlopně * metody   MeSH
• hospitalizace statistika a číselné údaje   MeSH
• konzervativní terapie * metody   MeSH
• lidé středního věku MeSH
• lidé MeSH
• následné studie MeSH
• pozorné vyčkávání MeSH
• senioři MeSH
• tepový objem fyziologie   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• randomizované kontrolované studie MeSH
• srovnávací studie MeSH

BACKGROUND: The initial rhythm is a known predictor of survival in extracorporeal cardiopulmonary resuscitation (ECPR) patients. However, the effect of the rhythm at hospital admission on outcomes in these patients is less clear. METHODS: This observational, single-center study assessed the influence of the rhythm at hospital admission on 30-day survival and neurological outcomes at discharge in patients who underwent ECPR for out-of-hospital cardiac arrest (OHCA). RESULTS: Between January 2012 and December 2023, 1,219 OHCA patients were admitted, and 210 received ECPR. Of these, 196 patients were analyzed. The average age was 52.9 years (±13), with 80.6 % male. The median time to ECPR initiation was 61 min (IQR 54-72). Patients with ventricular fibrillation as both the initial and admission rhythm had the highest 30-day survival rate (52 %: 35/67), while those with asystole in both instances had the lowest (6 %: 1/17, log-rank p < 0.00001). After adjusting for age, sex, initial rhythm, resuscitation time, location, bystander, and witnessed status, asystole at admission was linked to higher 30-day mortality (OR 4.03, 95 % CI 1.49-12.38, p = 0.009) and worse neurological outcomes (Cerebral Performance Category 3-5) at discharge (OR 4.61, 95 % CI 1.49-17.62, p = 0.013). CONCLUSIONS: The rhythm at hospital admission affects ECPR outcomes. Patients presenting with and maintaining ventricular fibrillation have a higher chance of favorable neurological survival, whereas those presenting with or converting to asystole have poor outcomes. The rhythm at hospital admission appears to be a valuable criterion for deciding on ECPR initiation.

• MeSH
• dospělí MeSH
• fibrilace komor terapie   mortalita   komplikace   MeSH
• hospitalizace statistika a číselné údaje   MeSH
• kardiopulmonální resuscitace * metody   statistika a číselné údaje   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mimotělní membránová oxygenace * metody   statistika a číselné údaje   MeSH
• míra přežití trendy   MeSH
• příjem pacientů statistika a číselné údaje   MeSH
• retrospektivní studie MeSH
• senioři MeSH
• srdeční frekvence fyziologie   MeSH
• zástava srdce mimo nemocnici * terapie   mortalita   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• pozorovací studie MeSH

We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.

• MeSH
• COVID-19 * prevence a kontrola   epidemiologie   MeSH
• dospělí MeSH
• hospitalizace * statistika a číselné údaje   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• SARS-CoV-2 * imunologie   MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• studie případů a kontrol MeSH
• účinost vakcíny * statistika a číselné údaje   MeSH
• vakcinace * statistika a číselné údaje   MeSH
• vakcíny proti COVID-19 * imunologie   aplikace a dávkování   MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• Geografické názvy
• Evropa MeSH

BACKGROUND: We need to better understand the risk factors and predictors of medication-related weight gain to improve metabolic health of individuals with schizophrenia. This study explores how trajectories of antipsychotic medication (AP) use impact body weight early in the course of schizophrenia. METHODS: We recruited 92 participants with first-episode psychosis (FEP, n = 92) during their first psychiatric hospitalization. We prospectively collected weight, body mass index (BMI), metabolic markers, and exact daily medication exposure during 6-week hospitalization. We quantified the trajectory of AP medication changes and AP polypharmacy using a novel approach based on meta-analytical ranking of medications and tested it as a predictor of weight gain together with traditional risk factors. RESULTS: Most people started treatment with risperidone (n = 57), followed by olanzapine (n = 29). Then, 48% of individuals remained on their first prescribed medication, while 33% of people remained on monotherapy. Almost half of the individuals (39/92) experienced escalation of medications, mostly switch to AP polypharmacy (90%). Only baseline BMI was a predictor of BMI change. Individuals in the top tercile of weight gain, compared to those in the bottom tercile, showed lower follow-up symptoms, a trend for longer prehospitalization antipsychotic treatment, and greater exposure to metabolically problematic medications. CONCLUSIONS: Early in the course of illness, during inpatient treatment, baseline BMI is the strongest and earliest predictor of weight gain on APs and is a better predictor than type of medication, polypharmacy, or medication switches. Baseline BMI predicted weight change over a period of weeks, when other traditional predictors demonstrated a much smaller effect.

• MeSH
• antipsychotika * terapeutické užití   škodlivé účinky   MeSH
• dospělí MeSH
• hmotnostní přírůstek * účinky léků   MeSH
• hospitalizace * statistika a číselné údaje   MeSH
• index tělesné hmotnosti * MeSH
• lidé MeSH
• mladý dospělý MeSH
• olanzapin terapeutické užití   MeSH
• polypharmacy MeSH
• prospektivní studie MeSH
• psychotické poruchy * farmakoterapie   MeSH
• risperidon terapeutické užití   škodlivé účinky   MeSH
• rizikové faktory MeSH
• schizofrenie * farmakoterapie   MeSH
• Check Tag
• dospělí MeSH
• lidé MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH

BACKGROUND: Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction has not been established. Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed. METHODS: In this international, double-blind trial, we randomly assigned patients with heart failure and a left ventricular ejection fraction of 40% or greater, in a 1:1 ratio, to receive finerenone (at a maximum dose of 20 mg or 40 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of total worsening heart failure events (with an event defined as a first or recurrent unplanned hospitalization or urgent visit for heart failure) and death from cardiovascular causes. The components of the primary outcome and safety were also assessed. RESULTS: Over a median follow-up of 32 months, 1083 primary-outcome events occurred in 624 of 3003 patients in the finerenone group, and 1283 primary-outcome events occurred in 719 of 2998 patients in the placebo group (rate ratio, 0.84; 95% confidence interval [CI], 0.74 to 0.95; P = 0.007). The total number of worsening heart failure events was 842 in the finerenone group and 1024 in the placebo group (rate ratio, 0.82; 95% CI, 0.71 to 0.94; P = 0.006). The percentage of patients who died from cardiovascular causes was 8.1% and 8.7%, respectively (hazard ratio, 0.93; 95% CI, 0.78 to 1.11). Finerenone was associated with an increased risk of hyperkalemia and a reduced risk of hypokalemia. CONCLUSIONS: In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo. (Funded by Bayer; FINEARTS-HF ClinicalTrials.gov number, NCT04435626.).

• MeSH
• antagonisté mineralokortikoidních receptorů * aplikace a dávkování   škodlivé účinky   MeSH
• dvojitá slepá metoda MeSH
• hospitalizace statistika a číselné údaje   MeSH
• Kaplanův-Meierův odhad MeSH
• lidé středního věku MeSH
• lidé MeSH
• naftyridiny * aplikace a dávkování   škodlivé účinky   MeSH
• následné studie MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• srdeční selhání * farmakoterapie   mortalita   patofyziologie   MeSH
• tepový objem * účinky léků   fyziologie   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• klinické zkoušky, fáze III MeSH
• multicentrická studie MeSH
• randomizované kontrolované studie MeSH

Cíl: Vzhledem k nedostatku údajů o frekvenci a závažnosti infekce vyvolané respiračním syncytiálním virem v České republice u dětí ve věku do 1 roku byla provedena analýza dostupných dat o hospitalizaci a odhad rizika hospitalizace v jednotlivých věkových skupinách. Metodiky: K analýzám byla použita data z Národního registru hrazených zdravotních služeb a Národního registru hospitalizací. Počty hospitalizací a úmrtí s diagnózou infekcí v letech 2017–2022 (diagnózy J12.1, J20.5, J21.0) byly analyzovány podle věku v jednotlivých měsících 1. roku života. Výsledky: Ve sledovaném období bylo celkem evidováno 4 356 hospitalizací s uvedenými diagnózami, v jednotlivých letech jich bylo zjištěno 172–1 445. Při přepočtu na 100 000 obyvatel a rok bylo odhadnuto celkové riziko hospitalizace s diagnózami J12.1, J20.5 a J21.0 na 656,26; nejnižší v roce 2020 (156,29) a nejvyšší v roce 2021 (1 294,12). Při analýze podle věkových skupin bylo nejvyšší riziko kalkulováno pro věkovou skupinu dětí do 6 měsíců (953,97/100 000 obyvatel a rok). Děti do 6 měsíců tvořily z celkového počtu hospitalizovaných dětí do 1 roku 72,7 %; nejvyšší počet hospitalizací byl u nich pozorován ve věku 1–3 měsíců. Jako nejčastější příčina hospitalizace s infekcí RSV byla zjištěna bronchitida, která byla uváděna v 55,4 % diagnóz. Během 6 let bylo hospitalizováno 3 771 donošených dětí a 585 nedonošených (13,4 %). U 4 356 hospitalizovaných s diagnózou J12.1, J20.5 a J21.0 bylo nahlášeno 22 úmrtí, tj. 0,5 %. Závěry: Infekce respiračním syncytiálním virem jsou uváděny jako příčina hospitalizace v České republice ve všech věkových sku- pinách. Nejvyšší riziko hospitalizace bylo v letech 2017–2022 odhadnuto pro děti ve věku do 6 měsíců. Pasivní surveillance na základě existujících registrů může být považována v současnosti za dostatečný podklad pro cílená specifická opatření v nejmladších věkových skupinách.

Objectives: Due to the lack of data on the frequency and seriousness of respiratory syncytial virus (RSV) infection in the Czech Republic among children under 1 year, an analysis was made of available data on hospitalizations and the risk of hospitalization was estimated for different age groups. Methods: Data from the Registry of Reimbursed Health Services and the National Registry of Hospitalizations were used for the analyses. Hospitalizations and deaths due to RSV infection (diagnoses J12.1, J20.5, J21.0) from 2017-2022 were analysed by month of the first year of life. Results: Over the study period, there were 4,356 hospitalizations with the above diagnoses, ranging between years from 172 to 1,445. The estimated overall hospitalization risk per 100,000 population and year for diagnoses J12.1, J20.5, and J21.0 was 656.26, varying between 156.29 (2020) and 1,294.12 (2021). Age-group analysis showed the highest risk for children under 6 months of age (953.97/100,000 population per year). They accounted for 72.7% of the total of hospitalizations in patients under 1 year of age, with the highest number of hospitalizations observed in 1-3-month-olds. The most frequent cause of hospitalizations with RSV infection was bronchitis, representing 55.4% of the above diagnoses. During the 6-year period, 3,771 full-term infants and 585 (13.4%) preterm infants were hospitalized. Among those 4,356 hospitalized with diagnoses J12.1, J20.5, and J21.0, 22 deaths (0.5%) were reported. Conclusions: RSV-associated hospitalizations have been recorded in all age groups in the Czech Republic. The highest RSV-associated hospitalization risk in 2017–2022 was estimated among children under 6 months of age. Passive surveillance using the available registries can be currently considered as an appropriate basis for adopting targeted measures specifically tailored to the youngest age categories.

• MeSH
• hospitalizace statistika a číselné údaje   MeSH
• infekce respiračními syncytiálními viry * diagnóza   epidemiologie   MeSH
• kojenec MeSH
• lidé MeSH
• novorozenec MeSH
• respirační syncytiální viry MeSH
• Check Tag
• kojenec MeSH
• lidé MeSH
• novorozenec MeSH
• Geografické názvy
• Česká republika MeSH

PURPOSE: Incident delirium is a frequent complication among hospitalized older people with COVID-19, associated with increased length of hospital stay, higher morbidity and mortality rates. Although delirium is preventable with early detection, systematic assessment methods and predictive models are not universally defined, thus delirium is often underrated. In this study, we tested the role of the Multidimensional Prognostic Index (MPI), a prognostic tool based on Comprehensive Geriatric Assessment, to predict the risk of incident delirium. METHODS: Hospitalized older patients (≥ 65 years) with COVID-19 infection were enrolled (n = 502) from ten centers across Europe. At hospital admission, the MPI was administered to all the patients and two already validated delirium prediction models were computed (AWOL delirium risk-stratification score and Martinez model). Delirium occurrence during hospitalization was ascertained using the 4A's Test (4AT). Accuracy of the MPI and the other delirium predictive models was assessed through logistic regression models and the area under the curve (AUC). RESULTS: We analyzed 293 patients without delirium at hospital admission. Of them 33 (11.3%) developed delirium during hospitalization. Higher MPI score at admission (higher multidimensional frailty) was associated with higher risk of incident delirium also adjusting for the other delirium predictive models and COVID-19 severity (OR = 12.72, 95% CI = 2.11-76.86 for MPI-2 vs MPI-1, and OR = 33.44, 95% CI = 4.55-146.61 for MPI-3 vs MPI-1). The MPI showed good accuracy in predicting incident delirium (AUC = 0.71) also superior to AWOL tool, (AUC = 0.63) and Martinez model (AUC = 0.61) (p < 0.0001 for both comparisons). CONCLUSIONS: The MPI is a sensitive tool for early identification of older patients with incident delirium.

• MeSH
• COVID-19 * komplikace   epidemiologie   diagnóza   MeSH
• delirium * diagnóza   epidemiologie   MeSH
• geriatrické hodnocení * metody   MeSH
• hodnocení rizik MeSH
• hospitalizace * statistika a číselné údaje   MeSH
• incidence MeSH
• lidé MeSH
• prognóza MeSH
• prospektivní studie MeSH
• rizikové faktory MeSH
• SARS-CoV-2 MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• Check Tag
• lidé MeSH
• mužské pohlaví MeSH
• senioři nad 80 let MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• multicentrická studie MeSH
• Geografické názvy
• Evropa MeSH

BACKGROUND: Anti-inflammatory therapy with long-term colchicine prevented vascular recurrence in coronary disease. Unlike coronary disease, which is typically caused by atherosclerosis, ischaemic stroke is caused by diverse mechanisms including atherosclerosis and small vessel disease or is frequently due to an unknown cause. We aimed to investigate the hypothesis that long-term colchicine would reduce recurrent events after ischaemic stroke. METHODS: We did a randomised, parallel-group, open-label, blinded endpoint assessed trial comparing long-term colchicine (0·5 mg orally per day) plus guideline-based usual care with usual care only. Hospital-based patients with non-severe, non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack were eligible. The primary endpoint was a composite of first fatal or non-fatal recurrent ischaemic stroke, myocardial infarction, cardiac arrest, or hospitalisation (defined as an admission to an inpatient unit or a visit to an emergency department that resulted in at least a 24 h stay [or a change in calendar date if the hospital admission or discharge times were not available]) for unstable angina. The p value for significance was 0·048 to adjust for two prespecified interim analyses conducted by the data monitoring committee, for which the steering committee and trial investigators remained blinded. The trial was registered at ClinicalTrials.gov (NCT02898610) and is completed. FINDINGS: 3154 patients were randomly assigned between Dec 19, 2016, and Nov 21, 2022, with the last follow-up on Jan 31, 2024. The trial finished before the anticipated number of outcomes was accrued (367 outcomes planned) due to budget constraints attributable to the COVID-19 pandemic. Ten patients withdrew consent for analysis of their data, leaving 3144 patients in the intention-to-treat analysis: 1569 (colchicine and usual care) and 1575 (usual care alone). A primary endpoint occurred in 338 patients, 153 (9·8%) of 1569 patients allocated to colchicine and usual care and 185 (11·7%) of 1575 patients allocated to usual care alone (incidence rates 3·32 vs 3·92 per 100 person-years, hazard ratio 0·84; 95% CI 0·68-1·05, p=0·12). Although no between-group difference in C-reactive protein (CRP) was observed at baseline, patients treated with colchicine had lower CRP at 28 days and at 1, 2, and 3 years (p<0·05 for all timepoints). The rates of serious adverse events were similar in both groups. INTERPRETATION: Although no statistically significant benefit was observed on the primary intention-to-treat analysis, the findings provide new evidence supporting the rationale for anti-inflammatory therapy in further randomised trials. FUNDING: Health Research Board Ireland, Deutsche Forschungsgemeinschaft (German Research Foundation), and Fonds Wetenschappelijk Onderzoek Vlaanderen (Research Foundation Flanders), Belgium.

• MeSH
• cévní mozková příhoda prevence a kontrola   MeSH
• hospitalizace statistika a číselné údaje   MeSH
• infarkt myokardu prevence a kontrola   MeSH
• ischemická cévní mozková příhoda * prevence a kontrola   MeSH
• kolchicin * aplikace a dávkování   terapeutické užití   MeSH
• lidé středního věku MeSH
• lidé MeSH
• recidiva MeSH
• sekundární prevence * metody   MeSH
• senioři MeSH
• tranzitorní ischemická ataka prevence a kontrola   farmakoterapie   MeSH
• výsledek terapie MeSH
• Check Tag
• lidé středního věku MeSH
• lidé MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• randomizované kontrolované studie MeSH

PURPOSE: To describe temporal trends in inpatient care use for adult mental disorders in Czechia from 1994 until 2015. METHODS: Data from the nationwide register of inpatient care use and yearly census data were used to calculate (a) yearly admissions rates, (b) median length of stay, and (c) standardized inpatient-years for adult mental disorders (ICD-10 codes F0-F6] or G30). Segmented regressions were used to analyze age- and sex-specific temporal trends. RESULTS: Admission rates were increasing in adults (average annual percent change = 0.51; 95% confidence interval = 0.16 to 0.86 for females and 1.01; 0.63 to 1.40 for males) and adolescents and emerging adults (3.27; 2.57 to 3.97 for females and 2.98; 2.08 to 3.88 for males), whereas in seniors, the trend was stable (1.22; -0.31 to 2.73 for females and 1.35; -0.30 to 2.98 for males). The median length of stay for studied mental disorders decreased across all age and sex strata except for a stable trend in male adolescents and emerging adults (-0.96; -2.02 to 0.10). Standardized inpatient-years were decreasing in adults of both sexes (-0.85; -1.42 to -0.28 for females and -0.87; -1.19 to -0.56 for males), increasing in female adolescents and emerging adults (0.95; 0.42 to 1.47), and stable in the remaining strata. CONCLUSION: Psychiatric hospital admissions were increasing or stable coupled with considerable reductions in median length of stay, suggesting that inpatient episodes for adult mental disorders have become more frequent and shorter over time. The overall psychiatric inpatient care use was decreasing or stable in adults and seniors, potentially implying a gradual shift away from hospital-based care.

• MeSH
• délka pobytu * statistika a číselné údaje   MeSH
• dospělí MeSH
• duševní poruchy * terapie   epidemiologie   MeSH
• hospitalizace * statistika a číselné údaje   trendy   MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• pacienti hospitalizovaní * statistika a číselné údaje   MeSH
• příjem pacientů statistika a číselné údaje   trendy   MeSH
• registrace * MeSH
• senioři MeSH
• Check Tag
• dospělí MeSH
• lidé středního věku MeSH
• lidé MeSH
• mladiství MeSH
• mladý dospělý MeSH
• mužské pohlaví MeSH
• senioři MeSH
• ženské pohlaví MeSH
• Publikační typ
• časopisecké články MeSH
• Geografické názvy
• Česká republika MeSH